Core Viewpoint - Meierjian Biological Products (Shanghai) Co., Ltd. has been established with a registered capital of 5 million RMB, fully owned by Meierjian Biotechnology (Shanghai) Co., Ltd. [1] Company Information - The legal representative of Meierjian Biological Products (Shanghai) Co., Ltd. is Liu Bizuo [1] - The company is classified under the manufacturing industry, specifically in the chemical raw materials and chemical products manufacturing sector [1] - The registered address is located at No. 101, South District, 1st Floor, Building 1, 159 Cailun Road, China (Shanghai) Pilot Free Trade Zone [1] - The company type is a limited liability company (wholly foreign-owned enterprise) [1] - The business license allows for various activities including marine biological active substance extraction, purification, and synthesis technology research and development [1] Business Scope - The operational scope includes research and application of cell technology, manufacturing of specialized chemical products (excluding hazardous chemicals), medical research and experimental development, and development of human stem cell technology [1] - The company is also involved in human genetic diagnosis and treatment technology development, import and export of goods, and daily chemical product manufacturing [1] - Licensed projects include medical beauty services, life beauty services, and cosmetics production, which require approval from relevant authorities before commencement [1]

Group 1 - The stock price of Jindalai (688057) closed at 12.65 yuan on January 9, 2026, reflecting a 3.52% increase from the previous week's price of 12.22 yuan [1] - The highest intraday price for Jindalai on January 9 was 12.71 yuan, while the lowest intraday price on January 5 was 12.23 yuan [1] - Jindalai's current total market capitalization is 3.491 billion yuan, ranking 70th out of 106 in the environmental governance sector and 4329th out of 5182 in the A-share market [1] Group 2 - The company plans to invest 280 million yuan in Jici Medical, acquiring a 34.00% stake, focusing on autologous cell technology research and development [2] - Jindalai is also increasing its investment in Zhongke Hongtai to enter the vascular interventional surgical robot field, with products currently undergoing special review procedures for national innovative medical devices [2]

Group 1 - The establishment of Zhongshe Telomere Regeneration Health Technology (Hunan) Co., Ltd. has been officially registered with a capital of 5 million RMB [1] - The company is involved in various business activities including food sales, tea product production, and alcohol-related operations, which require specific approvals [1] - The general business scope includes health consulting services, cell technology research and application, and remote health management services among others [1] Group 2 - The company also engages in technology services, technical development, and marketing planning, indicating a diverse operational focus [1] - Additional activities include the sale of health food, biological feed research, and various retail services, showcasing a broad market approach [1] - The company is positioned to leverage artificial intelligence in industry applications, reflecting a modern technological integration [1]

Core Insights - Lianyungang Tongyuan Cell Gene Engineering Co., Ltd. has been established with a registered capital of 3 million RMB, fully owned by Tongyuan Pathology Diagnosis Center (Jiangsu) Co., Ltd. [1] Company Overview - The legal representative of the company is Pan Jiagan [1] - The company is classified under the scientific research and technical service industry, specifically in engineering and technical research and development [1] - The business address is located at No. 567 Huaguoshan Avenue, Building 5, 6th Floor, China Medicine Port, Lianyungang Economic and Technological Development Zone [1] Business Scope - The company's business scope includes medical beauty services, life beauty services, drug clinical trial services, cosmetics production, leasing of Class III medical equipment, and operation of Class III medical devices [1] - It also involves cell technology research and application, engineering and technical research and experimental development, human stem cell technology development and application, and various technical services [1] - Additional services include internet data services, big data services, and sales of medical devices and cosmetics [1]

Group 1 - Shandong Mingxiang Biotechnology Co., Ltd. has been established with a registered capital of 10 million yuan, focusing on biomass energy technology services and comprehensive utilization of agricultural and forestry waste [1][2] - The company is co-owned by He Feng Food Co., Ltd. (35% share), Yafang New Ge Feng Agricultural Technology Co., Ltd. (35% share), and Pufang He Guangyuan Animal Health Co., Ltd. (30% share) [3] - The business scope includes cell technology research and application, livestock and fishery feed sales, and animal health monitoring [2][3] Group 2 - The company is located in Gaomi City, Shandong Province, and is registered under the High-Mi City Market Supervision Administration [2] - The operational period of the company is set until July 30, 2025, with no fixed expiration date [2] - The company is classified under the scientific research and technical services industry [2]

Core Viewpoint - Sartorius has expanded its cell technology product line by integrating MatTek into its laboratory products and services division, creating synergies with existing drug development solutions, including cell analysis instruments, reagents, and AI models [1][2]. Group 1: Acquisition Details - Sartorius officially completed the acquisition of MatTek, a subsidiary of BICO Group, on July 1, 2025 [2]. - The acquisition aims to enhance Sartorius's capabilities in cell technology and drug development [2]. Group 2: MatTek Overview - MatTek is a leading developer and manufacturer of human cell microtissues and three-dimensional models, focused on accelerating drug development processes [3]. - The advanced cell models developed by MatTek simulate the structure and function of human tissues, providing more accurate, cost-effective, and reproducible results compared to traditional two-dimensional cell cultures, while also reducing the need for animal testing [3]. - MatTek employs over 80 staff and is headquartered in Ashland, Massachusetts, with a production facility in Bratislava, Slovakia [3].